Anticholinergic drugs have been widely used for many years in neurological researchand clinical therapy of many diseases, such as parkinsonism, stomachache and theorganophosphorus agents poisoning. But these drugs are antagonists of muscarinicreceptors(M-receptors) and can hardly be used in the treatment of soman poisoning,because it is known in our institute that the potent antimuscarinic and certainantinicotinic activities are necessary for a highly effective drug against Soman poi-soning. In our previous works, we developed a theoretical model for the drug-receptorinteraction deduced from a conformation-activity relationship (CAN) of classic agonists Anticholinergic drugs have been widely used for many years in neurological research and clinical therapy of many diseases, such as parkinsonism, stomachache and theorganophosphorus agents poisoning. But these drugs are antagonists of muscarinic receptors (M-receptors) and can hardly be used in the treatment of soman poisoning, because it is known in our institute that the potent antimuscarinic and certainantinicotinic activities are necessary for a highly effective drug against Soman poi-soning. In our previous works, we developed a theoretical model for the drug-receptor interaction subtraced from a conformation-activity relationship (CAN) of classic agonists